Pancrelipase — Membership Pricing

Other medications in Digestive Health

• Plecanatide
• Polyethylene Glycol
• Prochlorperazine
• Prucalopride
• Psyllium
• Rabeprazole
• Senna
• Teduglutide

About Pancrelipase

Pancrelipase is a vital medication for individuals with pancreatic insufficiency, helping their bodies digest food properly. At TheDrugClub, we understand the importance of affordable access to essential prescriptions. Learn more about pancrelipase and discover how our membership can help you save significantly on this crucial medication, ensuring you get the care you need without breaking the bank.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Pancrelipase is approved for (FDA label)

VIOKACE, in combination with a proton pump inhibitor, is indicated for the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy in adults. VIOKACE, in combination with a proton pump inhibitor, is indicated for the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy in adults. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: August 14, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Pancrelipase (FDA label)

Tablets are available in the following strengths: 10,440 USP units of lipase; 39,150 USP units of protease; and 39,150 USP units of amylase as a tan, round, biconvex tablet with VIO9111 engraved on one side and 9111 on the other side. 20,880 USP units of lipase; 78,300 USP units of protease; and 78,300 USP units of amylase as a tan, oval, biconvex tablet with V 16 engraved on one side and 9116 on the other side. Tablets ( 3 ): 10,440 USP units of lipase; 39,150 USP units of protease; and 39,150 USP units of amylase 20,880 USP units of lipase; 78,300 USP units of protease; and 78,300 USP units of amylase

Source: FDA prescribing information (DailyMed). Set ID: 58bdb8de-582d-44e6-9b72-8d5a42fdf501. SPL document ID: 95ece3e2-a51f-4f4c-81ec-71aa2930a158. Label effective date: August 14, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Pancrelipase (FDA label)

The following serious or otherwise important adverse reactions are described elsewhere in the labeling: Fibrosing Colonopathy [see Warnings and Precautions (5.1) ] Irritation of the Oral Mucosa [see Warnings and Precautions (5.2) ] Hyperuricemia [see Warnings and Precautions (5.3) ] Risk of Viral Transmission [see Warnings and Precautions (5.4) ] Hypersensitivity Reactions [see Warnings and Precautions (5.5) ] Potential for Exacerbation of Symptoms of Lactose Intolerance [see Warnings and Precautions (5.6) ] Most common adverse reactions (≥7%) are: anal pruritus and biliary tract stones. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Aimmune Therapeutics, Inc at 1-833-AIM2KNO (1-833-246-2566) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1. Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 58bdb8de-582d-44e6-9b72-8d5a42fdf501. SPL document ID: 95ece3e2-a51f-4f4c-81ec-71aa2930a158. Label effective date: August 14, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Pancrelipase (FDA label)

None. None. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 58bdb8de-582d-44e6-9b72-8d5a42fdf501. SPL document ID: 95ece3e2-a51f-4f4c-81ec-71aa2930a158. Label effective date: August 14, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Pancrelipase (FDA label)

Fibrosing Colonopathy : Associated with high doses, usually over prolonged use and in pediatric patients with cystic fibrosis. Colonic stricture reported in pediatric patients less than 12 years of age with dosages exceeding 6,000 lipase units/kg/meal. Monitor during treatment for progression of preexisting disease. Do not exceed the recommended dosage, unless clinically indicated. ( 2.1 , 5.1 ) Irritation of the Oral Mucosa : May occur if tablets are crushed or chewed. ( 5.2 ) Hyperuricemia : Reported with high dosages, consider monitoring blood uric acid levels in patients with gout, renal impairment, or hyperuricemia. ( 5.3 ) Risk of Viral Transmission : The presence of porcine viruses that might infect humans cannot be definitely excluded. ( 5.4 ) Hypersensitivity Reactions : Monitor patients with known reactions to proteins of porcine origin.

Source: FDA prescribing information (DailyMed). Set ID: 58bdb8de-582d-44e6-9b72-8d5a42fdf501. SPL document ID: 95ece3e2-a51f-4f4c-81ec-71aa2930a158. Label effective date: August 14, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.